Hypothesis A single subanesthetic dose of propofol will result in improved pain and quality
of life for the next 30 days in persons with chronic daily headache (CDH)
Specific objectives To measure the effect of a single infusion of propofol at 40 mcg / kg /
minute over 60 mins on headache-related quality of life (measured by the Headache Disability
Index) and on headache severity (measured by the Headache Index) in subjects with chronic
daily headache over 30 days45-47